T. Rowe Price Associates, Inc. 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:19 pm Sale | 2025-09-30 | 13G | KYMERA THERAPEUTICS INC KYMR | T. Rowe Price Associates, Inc. | 5,097,704 7.100% | -1,547,770 (-23.29%) | Filing |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | KYMERA THERAPEUTICS INC KYMR | T. Rowe Price Associates, Inc. | 6,645,474 10.300% | 646,218 (+10.77%) | Filing |
| 2024-02-12 10:07 am Purchase | 2024-01-31 | 13G | KYMERA THERAPEUTICS INC KYMR | T. Rowe Price Associates, Inc. | 5,999,256 10.100% | 658,842 (+12.34%) | Filing |
| 2024-02-12 10:03 am Purchase | 2023-12-31 | 13G | KYMERA THERAPEUTICS INC KYMR | T. Rowe Price Associates, Inc. | 5,340,414 9.600% | 961,255 (+21.95%) | Filing |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | KYMERA THERAPEUTICS INC KYMR | T. Rowe Price Associates, Inc. | 4,379,159 8.000% | -845,527 (-16.18%) | Filing |
| 2022-07-11 2:10 pm Purchase | 2022-06-30 | 13G | KYMERA THERAPEUTICS INC KYMR | T. Rowe Price Associates, Inc. | 5,224,686 10.100% | 1,674,158 (+47.15%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | KYMERA THERAPEUTICS INC KYMR | T. Rowe Price Associates, Inc. | 3,550,528 6.900% | 3,550,528 (New Position) | Filing |